Shorts

1:22

Why Fertility Talks Can’t Wait After a Cancer Diagnosis

4 months ago

Kassiane Saieed, DNP, AGNP-C

Jorge E. Cortes, MD, spoke with CancerNetwork® about updated findings from the phase 3 ASC4FIRST trial (NCT04971226) showing improved responses and tolerability with asciminib (Scemblix) vs other tyrosine kinase inhibitors like imatinib (Gleevec) among those with chronic myeloid leukemia in chronic phase (CML-CP).

0:58

Perseverance is Key With Asciminib in Chronic Myeloid Leukemia

4 months ago

Jorge E. Cortes, MD

Karen Reckamp, MD, MS, challenged leadership to move beyond traditional, volume-based work relative value unit (wRVU) metrics.

0:52

Reexamining Investigator Incentives for Clinical Research Beyond RVUs

4 months ago

Karen L. Reckamp, MD

0:51

Will Multi-Targeted Regimens Spell a Reduction of Chemotherapy in DLBCL?

4 months ago

Sonali M. Smith, MD

0:50

Can Tafasitamab/Lenalidomide Prolong Remission in High-Risk DLBCL?

4 months ago

Sonali M. Smith, MD

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Hannah Goulart, MD, spoke about findings from an analysis evaluating revumenib (Revuforj) maintenance after allogeneic stem cell transplantation among patients with acute myeloid leukemia.

0:35

Does Revumenib Have a Role in The Pediatric AML Setting?

4 months ago

Hannah Goulart, MD

David M. Waterhouse, MD, MPH, discussed findings from a chart review analysis, contextualized by a need to improve prostate cancer testing rates in the US.

Developing Governance for AI in Prostate Cancer Genetic Testing

4 months ago

David M. Waterhouse, MD, MPH

0:54

How Does Vorasidenib Impact the Tumor Microenvironment?

4 months ago

Timothy F. Cloughesy, MD

Fred Saad, MD, FRCS, CQ, FCAHS, stated that no significant differences in higher grade or serious adverse effects emerged among patients regardless of disease volume.

1:06

AE Profile of Lu-177-PSMA-617 Similar Among Low, High Volume mHPSC Groups

5 months ago

Fred Saad, MD

Praful Ravi, MB, BChir, MRCP, highlighted that residual PSMA-avid disease remained detectable on PET imaging in 100% of patients with metastatic HSPC at the 6-month mark.

0:59

PSMAtrack: 100% of mHSPC Group Show Residual PSMA-Avid Disease at 6 Months

5 months ago

Praful Ravi, MB, BChir, MRCP

0:30

How Does Abemaciclib Toxicity Translate from Breast to Gynecologic Cancers?

5 months ago

Jordyn Silverstein, MD

0:49

ADC Vs Standard Chemo Selection in Breast Cancer

5 months ago

Paolo Tarantino, MD, PhD

According to Nicholas Hornstein, MD, PhD, although it broke headlines last year, this year’s presentation for the BREAKWATER trial will be a victory lap.

1:19

What to Expect From the BREAKWATER Trial at ASCO 2026?

5 months ago

Nicholas James Hornstein, MD, PhD

0:55

Personalized Vaccine/Pembrolizumab: The ASCO Abstract to Watch in Glioblastoma

5 months ago

Sonikpreet Aulakh, MBBS, MD

As part of a program conducted at the University of Miami, researchers utilized the Laravel AI platform to identify patient cases and cross-trial comparisons within their platform.

1:11

AI in Cross-Trial Comparison: Optimizing Meta-Analyses in Oncology

5 months ago

Chinmay Jani, MD

0:49

Why are Experts Hopeful About the 2026 ASCO Annual Meeting?

5 months ago

Nicholas James Hornstein, MD, PhD

Nathan Goodyear, MD, discussed exercise as an interventional biologic therapy to supplement standard-of-care anticancer therapies.

1:17

Could Exercise Prime the Immune System for Systemic Anticancer Therapies?

5 months ago

Nathan Goodyear, MD

1:01

Daraxonrasib in 2L PDAC May be the GI Abstract of ASCO 2026

5 months ago

Nicholas James Hornstein, MD, PhD

Mary Steinbach, NP, APRN, highlighted the advantages of subcutaneous isatuximab-irfc delivered via an on-body injector (OBI), which conferred better patient-reported outcomes than the intravenous solution.

0:51

On-Body Injector Brings “Modern” Isatuximab Delivery for Multiple Myeloma

5 months ago

Mary Steinbach, NP, APRN

0:56

Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations

5 months ago

Dana Chase, MD

Following the FDA approval of ruxolitinib extended-release tablets (Jakafi XR) across different myelofibrosis, polycythemia vera, and graft-versus-host disease populations, Naveen Pemmaraju, MD, spoke with CancerNetwork® about what this regulatory decision may mean for hematologic oncology practice.

0:31

How Might Extended-Release Ruxolitinib Tablets Impact Delivery of Care?

5 months ago

Naveen Pemmaraju, MD

Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO, discussed the impact of the Waterless Empirical Taste Test on better identifying and proactively managing oral adverse effects, including dysgeusia, that emerge with talquetamab among patients with multiple myeloma.

0:47

Examining the Impact of the WETT Tool on Talquetamab-Related Oral AEs

5 months ago

Beth Faiman, PhD, MSN, APN-BC

0:55

Prior Interstitial Lung Disease and Ocular Toxicity Pose ADC Treatment Risks

5 months ago

Dana Chase, MD

1:22

Keep 3, Cut 3: Essential Oncology Journals

5 months ago

Balazs Halmos, MD, MS

1:25

The Four Types of Therapy for Second-Line Endometrial Cancer

5 months ago

Dana Chase, MD

1:15

The Ultimate Oncology Conference Bracket

5 months ago

Balazs Halmos, MD, MS

0:43

Expanding the Use of TILs in Metastatic Melanoma Care

5 months ago

Hua-Jay Cherng, MD, discussed how markers such as ctDNA and MRD can translate to actionable strategies for lymphomas.

0:58

Is There Potential for a More Minimally Invasive Alternative to Biopsy?

5 months ago

Hua-Jay J Cherng, MD

Hua-Jay Cherng, MD, discussed how clinicians may be able to get the most out of assessment tools that could be used to inform treatment decision-making processes among lymphoma groups.

1:24

Optimizing the Use of Assessment Tools in Lymphoma Care

5 months ago

Hua-Jay J Cherng, MD

A Potential Breakthrough With TILs in Metastatic Melanoma

Shorts

Trending on CancerNetwork

Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care

How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy

How to Work With a Patient Who Declines Cancer Treatment

Targeting Cyclin E1, KRAS, and DNA Repair Beyond PARP in Ovarian Cancer

Screening for Depression and Starting Antidepressants in Oncology Care